TFE3 fusion proteins are the oncogenic drivers of translocation renal cell carcinoma but their mechanism of action remains ...

A Phase Ia Dose-Escalation Study The article by Mascarenhas et al entitled “Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors” (J ...

Researcher suggests compounds secreted by high-risk MSCs that are detectable in the bloodstream could act as biomarkers for ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from preclinical studies of the Company’s internally ...

These cells are often found in heterogeneous tumors and include cancer stem-like cells (CSCs), cells undergoing epithelial-to ...

Cancer cells can alter their identity through epithelial-mesenchymal transition (EMT), a process that enhances their ability to spread. The researchers demonstrated that several proteins involved ...

A recent study published in Engineering has shed new light on the mechanisms underlying the metastasis of head and neck ...

Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors Patients who were 20 years or older, diagnosed in 2013-2019 with breast ...

Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

In a major advancement for ovarian cancer research, a team of scientists from the University of Pittsburgh has identified ...

Cancer remains a leading cause of death globally, with lung cancer being particularly lethal. Despite advancements in diagnostics and therapies, the five-year survival rates for advanced tumors have ...

Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing product development New tagline to emphasize the company’s ...